Epstein–Barr virus vaccine

Epstein–Barr virus vaccine is a term for a vaccine against the Epstein–Barr virus. The virus establishes persistent/latent infection and causes infectious mononucleosis. Vaccines are not yet available,[1] but it is in clinical trials.[2][3][4] The viral protein Gp350/220 is the primary target[5] and MVA-EL has been also proposed as a target.[6]

One challenge is that the Epstein–Barr virus expresses very different proteins during its lytic and its latent phases. To address this, vaccine candidates have been designed to include proteins from both phases.[7]

References

  1. ↑ Sokal, E.M., Hoppenbrouwers, K., Vandermeulen, C.; et al. (December 2007). "Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults". J. Infect. Dis. 196 (12): 1749–53. doi:10.1086/523813. PMID 18190254.
  2. ↑ Crawford, D.H., Macsween, K.F., Higgins, C.D.; et al. (August 2006). "A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis". Clin. Infect. Dis. 43 (3): 276–82. doi:10.1086/505400. PMID 16804839.
  3. ↑ Elliott, S.L., Suhrbier, A., Miles, J.J.; et al. (February 2008). "Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis". J. Virol. 82 (3): 1448–57. doi:10.1128/JVI.01409-07. PMC 2224445. PMID 18032491.
  4. ↑ Moutschen, M., Léonard, P., Sokal, E.M.; et al. (June 2007). "Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults". Vaccine 25 (24): 4697–705. doi:10.1016/j.vaccine.2007.04.008. PMID 17485150.
  5. ↑ "WHO | Viral Cancers". Retrieved 2009-01-15.
  6. ↑ Taylor, G.S., Haigh, T.A., Gudgeon, N.H.; et al. (January 2004). "Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma". J. Virol. 78 (2): 768–78. doi:10.1128/JVI.78.2.768-778.2004. PMC 368843. PMID 14694109.
  7. ↑ Lockey, T.D., Zhan, X., Surman, S., Sample, C.E., Hurwitz, J.L. (2008). "Epstein-Barr virus vaccine development: a lytic and latent protein cocktail". Front. Biosci. 13 (13): 5916–27. doi:10.2741/3126. PMID 18508632.


This article is issued from Wikipedia - version of the Monday, March 07, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.